prikaz prve stranice dokumenta A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?
  Preuzmi
PDF 175.73 KB
Znanstveni rad - Ostalo
A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?
Annals of Translational Medicine, 4 (2016), 9; 162. https://doi.org/10.21037/atm.2016.04.15
Sreter, Katherina-Bernadette; Jakopovic, Marko; Janevski, Zoran; Samarzija, Miroslav; Zarogoulidis, Paul; Kioumis, Ioannis; Mparmpetakis, Nikolaos; Pataka, Athanasia; Zarogoulidis, Konstantinos; Tsiouda, Theodora; Kosmidis, Christoforos; Mpaka, Sofia; Huang, Haidong; Hohenforst-Schmidt, Wolfgang; Charalampidis, Charalampos; Machairiotis, Nikolaos; Zaric, Bojan; Milovancev, Aleksandar Više autora...

Citirajte ovaj rad

Sreter, K. B., Jakopovic, M., Janevski, Z., Samarzija, M., Zarogoulidis, P., Kioumis, I. ... Milovancev, A. (2016). A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?. Annals of Translational Medicine, 4. (9). doi: 10.21037/atm.2016.04.15

Sreter, Katherina Bernadette, et al. "A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?." Annals of Translational Medicine, vol. 4, br. 9, 2016. https://doi.org/10.21037/atm.2016.04.15

Sreter, Katherina Bernadette, Marko Jakopovic, Zoran Janevski, Miroslav Samarzija, Paul Zarogoulidis, Ioannis Kioumis, Nikolaos Mparmpetakis, et al. "A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?." Annals of Translational Medicine 4, br. 9 (2016). https://doi.org/10.21037/atm.2016.04.15

Sreter, K. B., et al. (2016) 'A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?', Annals of Translational Medicine, 4(9). doi: 10.21037/atm.2016.04.15

Sreter KB, Jakopovic M, Janevski Z, Samarzija M, Zarogoulidis P, Kioumis I, i sur.. A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?. Annals of Translational Medicine [Internet]. 05.2016. [pristupljeno 22.11.2024.];4(9). doi: 10.21037/atm.2016.04.15

K. B. Sreter, et al., "A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?", Annals of Translational Medicine, vol. 4, br. 9, Svibanj 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:931880. [Citirano: 22.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:931880
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?
AutorKatherina-Bernadette Sreter
AutorMarko Jakopovic
AutorZoran Janevski
AutorMiroslav Samarzija
AutorPaul Zarogoulidis
AutorIoannis Kioumis
AutorNikolaos Mparmpetakis
AutorAthanasia Pataka
AutorKonstantinos Zarogoulidis
AutorTheodora Tsiouda
AutorChristoforos Kosmidis
AutorSofia Mpaka
AutorHaidong Huang
AutorWolfgang Hohenforst-Schmidt
AutorCharalampos Charalampidis
AutorNikolaos Machairiotis
AutorBojan Zaric
AutorAleksandar Milovancev
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Background: Lung cancer is the leading cause of malignant pleural effusion (MPE). Management of MPEs remains a clinical challenge due to recurrence and poor quality of life. An ideal sclerosing agent has yet to be found. The aim of this cohort pilot study was to evaluate the role of mitoxantrone pleurodesis (MP) as an alternative to talc sclerotherapy for managing MPEs in lung cancer patients. Methods: A retrospective chart review was conducted on consecutively admitted patients with MPE to the Department of Post-Intensive Care at the Clinic for Respiratory Diseases “Jordanovac”, University Hospital Centre Zagreb, in Croatia. Results: Of 34 patients with MPE, twenty-one (64.8±9.46 years; 47–84 years) with primary lung carcinoma who received MP (30 mg of mitoxantrone) between December 2003 and February 2009 were included in this study. Chest radiographs taken prior to sclerotherapy and at 1-, 2-, and 3-month follow-up were compared. At the post-sclerotherapy evaluation periods, overall success (OS) rates of MP were 88.2% [17.6%, complete response (CR); 70.6%, partial response (PR)], 53.9% (7.7% CR; 46.2% PR), and 45.5% (PR), respectively. Kaplan-Meier median survival from MP until death was 5.2 months, while that from diagnosis of primary lung cancer was 12.3 months. Conclusions: MP may be a safe and effective method of managing MPE due to lung cancer. Future randomized controlled studies comparing mitoxantrone and talc pleurodesis in lung cancer patients are warranted to elucidate whether a significant difference exists between these agents. Factors affecting success, survival probability, and quality of life also require further investigation.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Ostalo
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaAnnals of Translational Medicine
Brojčani podacivol. 4, br. 9, 162
p-ISSN2305-5839
e-ISSN2305-5847
DOIhttps://doi.org/10.21037/atm.2016.04.15
URN:NBNurn:nbn:hr:220:931880
Datum objave publikacije2016-05
URL dokumentahttp://atm.amegroups.com/article/view/10302/11041
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2024-09-20 11:12:40